Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

9

Feb 2026

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.

Cognitive speed training shows potential to delay dementia for two decades

9

Feb 2026

Cognitive speed training shows potential to delay dementia for two decades

Adults age 65 and older who completed five to six weeks of cognitive speed training - in this case, speed of processing training, which helps people quickly find visual information on a computer screen and handle increasingly complex tasks in a shorter time period - and who had follow-up sessions about one to three years later were less likely to be diagnosed with dementia, including Alzheimer's disease, up to two decades later, according to new findings published today in Alzheimer's & Dementia: Translational Research and Clinical Interventions.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.